Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

(2016) Paul T. Nghiem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes

(2016) Yaqing Qie et al.   Scientific Reports

CD47 blockade triggers T cell–mediated destruction of immunogenic tumors

(2015) Xiaojuan Liu et al.   NATURE MEDICINE

In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer

(2015) P. H. Lizotte et al.   Nature Nanotechnology

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Macrophages eat cancer cells using their own calreticulin as a guide: Roles of TLR and Btk

(2015) Mingye Feng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology

(2013) Michael Kalos et al.   IMMUNITY

Targeting of Antigens to B Lymphocytes via CD19 as a Means for Tumor Vaccine Development

(2013) Y. Ma et al.   JOURNAL OF IMMUNOLOGY

Engineered SIRP  Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies

(2013) K. Weiskopf et al.   SCIENCE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

A multifunctional core–shell nanoparticle for dendritic cell-based cancer immunotherapy

(2011) Nam-Hyuk Cho et al.   Nature Nanotechnology

Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response

(2011) Haiyan Li et al.   Nature Nanotechnology

The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity

(2010) SaeGwang Park et al.   CANCER CELL

Bispecific T-Cell Engaging Antibodies for Cancer Therapy

(2009) P. A. Baeuerle et al.   CANCER RESEARCH

Dendritic cell-based therapeutic cancer vaccines: what we have and what we need

(2009) Pawel Kalinski et al.   Future Oncology

Nanoparticle-mediated cellular response is size-dependent

(2008) Wen Jiang et al.   Nature Nanotechnology

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody

(2008) R. Bargou et al.   SCIENCE